Nalaganje...
Pharmacological or TRIB3-Mediated Suppression of ATF4 Transcriptional Activity Promotes Hepatoma Cell Resistance to Proteasome Inhibitor Bortezomib
SIMPLE SUMMARY: Proteasome inhibitors are currently used in the treatment of certain blood cancers, and clinical trials to treat solid tumors, including liver cancer, have also been conducted. However, different malignancies are not equally susceptible to proteasome inhibitors, and resistance to the...
Shranjeno v:
| izdano v: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI
2021
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8150958/ https://ncbi.nlm.nih.gov/pubmed/34066165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102341 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|